Jun 2026 (Q2 FY26) — Aug 5, 2026
Akebia Therapeutics Q2 FY26 — Vafseo Growth and Positive VOICE Trial Results
Read the full callAkebia Therapeutics (AKBA) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Akebia Therapeutics earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 49.1 | −21.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -12.9 | −35.4 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -8.9 | −3706.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$0.7 0.00% · $0
Performance −74.9% 1Y
1Y: $2.79 on 14 Oct 2025 → $0.7. High $3.17 (27 Oct 2025), low $0.7 (14 Oct 2026).
- Previous close
- $0.7
- 52-week range
- $0.7 – $3.17
- One year
- −76.27%
Overview
- Symbol
- AKBA
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Akebia Therapeutics earnings calls (AKBA)
Financials
What the filings say
Net profit, year on year: −3706% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 37 | 46 | 57 | 62 | 59 | 58 | 54 | 49 |
| Operating profit | -13 | -14 | 14 | 14 | 4 | -9 | -5 | -6 |
| Operating margin | −33.4% | −30.8% | 23.6% | 22.6% | 7.6% | −14.8% | −8.8% | −12.9% |
| Profit before tax | -20 | -23 | 6 | 0 | 1 | -11 | -9 | -9 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 53.3% | −9.0% | −1.4% | −0.8% |
| Net profit | -20 | -23 | 6 | 0 | 1 | -12 | -9 | -9 |
| EPS ($ per share) | -0.10 | — | 0.03 | 0 | 0 | — | -0.03 | -0.03 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -514 | -794 | -1,178 | -1,463 | -1,557 | -1,609 | -1,678 | -1,684 |
| Total liabilities | 361 | 376 | 397 | 455 | 351 | 272 | 270 | 344 |
| Fixed assets | 8 | 10 | 9 | 7 | 5 | 4 | 2 | 1 |
| Total assets | 997 | 771 | 644 | 529 | 356 | 242 | 221 | 377 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -97 | -257 | -110 | -253 | -73 | -23 | -41 | 68 |
| Cash from investing | 37 | 211 | -40 | 40 | -0 | 0 | -0 | -8 |
| Cash from financing | 97 | 89 | 232 | 134 | 15 | -25 | 50 | 73 |
| Net cash flow | 36 | 43 | 81 | -79 | -59 | -49 | 9 | 133 |
| Capital expenditure | -2 | -7 | -0 | -0 | -0 | 0 | -0 | -0 |
| Free cash flow | -99 | -264 | -111 | -253 | -73 | -23 | -41 | 68 |
Insider filings
31 filings between Jan 30, 2026 and Aug 6, 2026.
Open market
decisions to buy or sellPurchases
$86.6K
1 purchase by 1 insider
Sales
$963.0K
16 sales by 6 insiders
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 13
- Award — granted as compensation
- 1
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Butler John P. | $86.6K | $474.4K | Mar 4, 2026 |
| Grund Nicholas | — | $117.9K | Feb 2, 2026 |
| Ostrowski Erik | — | $110.8K | Jun 29, 2026 |
| Rucci Carolyn M. | — | $97.0K | Feb 2, 2026 |
| Burke Steven Keith | — | $94.0K | Feb 2, 2026 |
| Malabre Richard C | — | $68.8K | Feb 2, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 6, 2026 | Butler John P. CEO and President | Option exercise | 350,000 | $220.5K |
| Jun 29, 2026 | Ostrowski Erik SVP, CFO, CBO & Treasurer | Sale 10b5-1 plan | 56,019 | $62.2K |
| Jun 17, 2026 | ZUMWALT LEANNE M Director | Award | 35,700 | $0 |
| Jun 17, 2026 | ADAMS ADRIAN Director | Award | 35,700 | $0 |
| Jun 17, 2026 | Wolf Myles Director | Award | 35,700 | $0 |
| Jun 17, 2026 | FRIESON RON Director | Award | 35,700 | $0 |
| Jun 17, 2026 | ROGERS MICHAEL W Director | Award | 35,700 | $0 |
| Jun 17, 2026 | Smith Cynthia Director | Award | 35,700 | $0 |
| Mar 4, 2026 | Butler John P. CEO and President | Purchase | 69,270 | $86.6K |
| Feb 2, 2026 | Grund Nicholas Chief Commercial Officer | Sale 10b5-1 plan | 53,585 | $74.5K |
| Feb 2, 2026 | Grund Nicholas Chief Commercial Officer | Sale 10b5-1 plan | 31,244 | $43.4K |
| Feb 2, 2026 | Ostrowski Erik SVP, CFO, CBO & Treasurer | Sale 10b5-1 plan | 34,951 | $48.6K |
| Feb 2, 2026 | Malabre Richard C SVP, Chief Accounting Officer | Sale 10b5-1 plan | 36,142 | $50.2K |
| Feb 2, 2026 | Malabre Richard C SVP, Chief Accounting Officer | Sale 10b5-1 plan | 13,382 | $18.6K |
| Feb 2, 2026 | Rucci Carolyn M. SVP, Chief Legal Officer | Sale 10b5-1 plan | 16,846 | $23.4K |
| Feb 2, 2026 | Rucci Carolyn M. SVP, Chief Legal Officer | Sale 10b5-1 plan | 25,382 | $35.3K |
| Feb 2, 2026 | Rucci Carolyn M. SVP, Chief Legal Officer | Sale 10b5-1 plan | 27,544 | $38.3K |
| Feb 2, 2026 | Butler John P. CEO and President | Sale 10b5-1 plan | 96,065 | $133.5K |
| Feb 2, 2026 | Butler John P. CEO and President | Sale 10b5-1 plan | 46,660 | $64.9K |
| Feb 2, 2026 | Butler John P. CEO and President | Sale 10b5-1 plan | 114,891 | $159.7K |
| Feb 2, 2026 | Butler John P. CEO and President | Award 10b5-1 plan | 175,250 | $247.1K |
| Feb 2, 2026 | Butler John P. CEO and President | Sale 10b5-1 plan | 83,689 | $116.3K |
| Feb 2, 2026 | Burke Steven Keith SVP, Chief Medical Officer | Sale 10b5-1 plan | 21,582 | $30.0K |
| Feb 2, 2026 | Burke Steven Keith SVP, Chief Medical Officer | Sale 10b5-1 plan | 25,375 | $35.3K |
| Feb 2, 2026 | Burke Steven Keith SVP, Chief Medical Officer | Sale 10b5-1 plan | 20,701 | $28.8K |
| Jan 30, 2026 | Ostrowski Erik SVP, CFO, CBO & Treasurer | Award | 204,000 | $0 |
| Jan 30, 2026 | Butler John P. CEO and President | Award | 743,000 | $0 |
| Jan 30, 2026 | Burke Steven Keith SVP, Chief Medical Officer | Award | 204,000 | $0 |
| Jan 30, 2026 | Grund Nicholas Chief Commercial Officer | Award | 204,000 | $0 |
| Jan 30, 2026 | Malabre Richard C SVP, Chief Accounting Officer | Award | 79,000 | $0 |
| Jan 30, 2026 | Rucci Carolyn M. SVP, Chief Legal Officer | Award | 190,000 | $0 |
| Jun 30, 2025 | Ostrowski Erik SVP, CFO, CBO & Treasurer | Sale 10b5-1 plan | 41,314 | $151.6K |
| Jun 10, 2025 | ZUMWALT LEANNE M Director | Award | 35,700 | $0 |
| Jun 10, 2025 | FRIESON RON Director | Award | 35,700 | $0 |
| Jun 10, 2025 | GILMAN STEVEN C Director | Award | 35,700 | $0 |
| Jun 10, 2025 | ROGERS MICHAEL W Director | Award | 35,700 | $0 |
| Jun 10, 2025 | Smith Cynthia Director | Award | 35,700 | $0 |
| Jun 10, 2025 | ADAMS ADRIAN Director | Award | 35,700 | $0 |
| Jun 10, 2025 | Wolf Myles Director | Award | 35,700 | $0 |
| Jun 9, 2025 | Malabre Richard C SVP, Chief Accounting Officer | Option exercise 10b5-1 plan | 15,000 | $25.2K |
| Jun 9, 2025 | Malabre Richard C SVP, Chief Accounting Officer | Sale 10b5-1 plan | 15,000 | $60.1K |
| Jun 4, 2025 | Malabre Richard C SVP, Chief Accounting Officer | Sale 10b5-1 plan | 13,334 | $47.1K |
| Mar 3, 2025 | Butler John P. CEO and President | Sale 10b5-1 plan | 46,409 | $84.9K |
| Mar 3, 2025 | Burke Steven Keith SVP, Chief Medical Officer | Sale 10b5-1 plan | 7,144 | $13.1K |
| Feb 3, 2025 | Burke Steven Keith SVP, Chief Medical Officer | Sale 10b5-1 plan | 23,270 | $48.9K |
| Feb 3, 2025 | Burke Steven Keith SVP, Chief Medical Officer | Sale 10b5-1 plan | 27,236 | $57.2K |
| Feb 3, 2025 | Malabre Richard C SVP, Chief Accounting Officer | Sale 10b5-1 plan | 30,202 | $63.4K |
| Feb 3, 2025 | Butler John P. CEO and President | Sale 10b5-1 plan | 46,268 | $97.2K |
| Feb 3, 2025 | Butler John P. CEO and President | Sale 10b5-1 plan | 97,982 | $205.8K |
| Feb 3, 2025 | Grund Nicholas Chief Commercial Officer | Sale 10b5-1 plan | 55,621 | $116.8K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Akebia Therapeutics, Inc.
Free account. Everything above stays public.
Write why you follow Akebia Therapeutics, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading